BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baicus A. History of polio vaccination. World J Virol 2012; 1(4): 108-114 [PMID: 24175215 DOI: 10.5501/wjv.v1.i4.108] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Teixeira AG, Agarwal R, Ko KR, Grant-Burt J, Leung BM, Frampton JP. Emerging Biotechnology Applications of Aqueous Two-Phase Systems. Adv Healthc Mater 2018;7:e1701036. [PMID: 29280350 DOI: 10.1002/adhm.201701036] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 8.8] [Reference Citation Analysis]
2 Kumar P, Sunita, Dubey KK, Shukla P. Whole-Cell Vaccine Preparation: Options and Perspectives. Methods Mol Biol 2021;2183:249-66. [PMID: 32959248 DOI: 10.1007/978-1-0716-0795-4_13] [Reference Citation Analysis]
3 Suarez GP, Udiani O, Allan BF, Price C, Ryan SJ, Lofgren E, Coman A, Stone CM, Gallos LK, Fefferman NH. A generic arboviral model framework for exploring trade-offs between vector control and environmental concerns. J Theor Biol 2020;490:110161. [PMID: 31953137 DOI: 10.1016/j.jtbi.2020.110161] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
4 Manukyan H, Petrovskaya S, Chumakov K, Laassri M. Multiplex PCR-Based Neutralization (MPBN) Assay for Titers Determination of the Three Types of Anti-Poliovirus Neutralizing-Antibodies. Vaccines (Basel) 2020;8:E120. [PMID: 32150852 DOI: 10.3390/vaccines8010120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Berner M, Pany-Kucera D, Doneus N, Sladek V, Gamble M, Eggers S. Challenging definitions and diagnostic approaches for ancient rare diseases: The case of poliomyelitis. Int J Paleopathol 2021;33:113-27. [PMID: 33894575 DOI: 10.1016/j.ijpp.2021.04.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pöyhönen L, Bustamante J, Casanova JL, Jouanguy E, Zhang Q. Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity. J Clin Immunol 2019;39:376-90. [PMID: 31123910 DOI: 10.1007/s10875-019-00642-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
7 Rodgers AM, Cordeiro AS, Donnelly RF. Technology update: dissolvable microneedle patches for vaccine delivery. Med Devices (Auckl) 2019;12:379-98. [PMID: 31572025 DOI: 10.2147/MDER.S198220] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
8 Patti AM, Katsiki N, Nikolic D, Al-rasadi K, Rizzo M. Nutraceuticals in Lipid-Lowering Treatment: A Narrative Review on the Role of Chitosan. Angiology 2015;66:416-21. [DOI: 10.1177/0003319714542999] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
9 Mir F, Quadri F, Mach O, Ahmed I, Bhatti Z, Khan A, Rehman NU, Durry E, Salama M, Oberste SM, Weldon WC, Sutter RW, Zaidi AK. Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial. Lancet Infect Dis 2015;15:889-97. [PMID: 26093979 DOI: 10.1016/S1473-3099(15)00093-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
10 Seeberger PH. Discovery of Semi- and Fully-Synthetic Carbohydrate Vaccines Against Bacterial Infections Using a Medicinal Chemistry Approach. Chem Rev 2021;121:3598-626. [PMID: 33794090 DOI: 10.1021/acs.chemrev.0c01210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Schleiff M, Olateju A, Decker E, Neel AH, Oke R, Peters MA, Rao A, Alonge O. A multi-pronged scoping review approach to understanding the evolving implementation of the Smallpox and Polio eradication programs: what can other Global Health initiatives learn? BMC Public Health 2020;20:1698. [PMID: 33339517 DOI: 10.1186/s12889-020-09439-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Mathis S, Soulages A, Le Masson G, Vallat JM. Epidemics and outbreaks of peripheral nervous system disorders: I. infectious and immune-mediated causes. J Neurol 2021;268:879-90. [PMID: 32914207 DOI: 10.1007/s00415-020-10215-9] [Reference Citation Analysis]
13 Honda-Okubo Y, Baldwin J, Petrovsky N. Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines. Pathogens 2021;10:500. [PMID: 33919442 DOI: 10.3390/pathogens10050500] [Reference Citation Analysis]
14 Elawar F, Oraby AK, Kieser Q, Jensen LD, Culp T, West FG, Marchant DJ. Pharmacological targets and emerging treatments for respiratory syncytial virus bronchiolitis. Pharmacol Ther 2021;220:107712. [PMID: 33121940 DOI: 10.1016/j.pharmthera.2020.107712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Manukyan H, Tritama E, Wahid R, Ansari A, Konz J, Chumakov K, Laassri M. Development of a Quantitative One-Step RT-PCR Method for the Detection of Sabin 2 Virus Contamination in a Novel Oral Poliovirus Vaccine Type 2. Vaccines (Basel) 2021;9:688. [PMID: 34201447 DOI: 10.3390/vaccines9070688] [Reference Citation Analysis]
16 Yoshikawa T. Vaccine Development for Severe Fever with Thrombocytopenia Syndrome. Viruses 2021;13:627. [PMID: 33917632 DOI: 10.3390/v13040627] [Reference Citation Analysis]
17 Derrough T, Salekeen A. Lessons learnt to keep Europe polio-free: a review of outbreaks in the European Union, European Economic Area, and candidate countries, 1973 to 2013. Euro Surveill 2016;21. [PMID: 27123992 DOI: 10.2807/1560-7917.ES.2016.21.16.30210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
18 Lerner AM, DeRocco AJ, Yang L, Robinson DA, Eisinger RW, Bushar ND, Nath A, Erbelding E. Unraveling the Mysteries of Acute Flaccid Myelitis: Scientific Opportunities and Priorities for Future Research. Clin Infect Dis 2021;72:2044-8. [PMID: 32964217 DOI: 10.1093/cid/ciaa1432] [Reference Citation Analysis]
19 Norins LC. Predicted economic damage from a quick, simple Alzheimer's disease cure. Medical Hypotheses 2019;133:109398. [DOI: 10.1016/j.mehy.2019.109398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Tasher D, Rahav G, Levine H, Sofer D, Linder N, Anis E, Shohat T, Manor Y, Kopel E, Shulman LM, Mendelson E, Shalit I, Somekh E. How many OPV rounds are required to stop wild polio virus circulation in a developed country? Lessons from the Israeli experience. Vaccine 2016;34:299-301. [PMID: 26679402 DOI: 10.1016/j.vaccine.2015.11.066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
21 D'Amelio E, Salemi S, D'Amelio R. Anti-Infectious Human Vaccination in Historical Perspective. Int Rev Immunol 2016;35:260-90. [PMID: 26606466 DOI: 10.3109/08830185.2015.1082177] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
22 Genito CJ, Batty CJ, Bachelder EM, Ainslie KM. Considerations for Size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases. Adv Nanobiomed Res 2021;:2000041. [PMID: 33681864 DOI: 10.1002/anbr.202000041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
23 Sun M, Li C, Xu W, Liao G, Li R, Zhou J, Li Y, Cai W, Yan D, Che Y, Ying Z, Wang J, Yang H, Ma Y, Ma L, Ji G, Shi L, Jiang S, Li Q. Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses. Clinical Infectious Diseases 2017;64:1317-25. [DOI: 10.1093/cid/cix110] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
24 Abba B, Abdullahi S, Bawa S, Getso KI, Bello IW, Korir C, Musa A, Braka F, Ningi A, Nsubuga P, Banda R, Tegegne SG, Shuaib F, Adamu US, Haladu S. Mobilizing political support proved critical to a successful switch from tOPV to bOPV in Kano, Nigeria 2016. BMC Public Health 2018;18:1302. [PMID: 30541496 DOI: 10.1186/s12889-018-6195-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
25 Saraf S, Jain S, Sahoo RN, Mallick S. Present Scenario of M-Cell Targeting Ligands for Oral Mucosal Immunization. CDT 2020;21:1276-84. [DOI: 10.2174/1389450121666200609113252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Blackwood CB, Sen-Kilic E, Boehm DT, Hall JM, Varney ME, Wong TY, Bradford SD, Bevere JR, Witt WT, Damron FH, Barbier M. Innate and Adaptive Immune Responses against Bordetella pertussis and Pseudomonas aeruginosa in a Murine Model of Mucosal Vaccination against Respiratory Infection. Vaccines (Basel) 2020;8:E647. [PMID: 33153066 DOI: 10.3390/vaccines8040647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Comunale BA, Engineer L, Jiang Y, Andrews JC, Liu Q, Ji L, Yurkovich JT, Comunale RA, Xie Q. Poliovirus Vaccination Induces a Humoral Immune Response That Cross Reacts With SARS-CoV-2. Front Med (Lausanne) 2021;8:710010. [PMID: 34414206 DOI: 10.3389/fmed.2021.710010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 New RRC. Formulation technologies for oral vaccines. Clin Exp Immunol 2019;198:153-69. [PMID: 31318446 DOI: 10.1111/cei.13352] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
29 Baird FJ, Lopata AL. The dichotomy of pathogens and allergens in vaccination approaches. Front Microbiol 2014;5:365. [PMID: 25076945 DOI: 10.3389/fmicb.2014.00365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
30 F Nahhas A, F Nahhas A, J Webster T. Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics. Nanomedicine (Lond) 2021;16:1237-54. [PMID: 33988037 DOI: 10.2217/nnm-2020-0447] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Perrin J, Capitao M, Mougin-Degraef M, Guérard F, Faivre-Chauvet A, Rbah-Vidal L, Gaschet J, Guilloux Y, Kraeber-Bodéré F, Chérel M, Barbet J. Cell Tracking in Cancer Immunotherapy. Front Med (Lausanne) 2020;7:34. [PMID: 32118018 DOI: 10.3389/fmed.2020.00034] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 20.0] [Reference Citation Analysis]
32 Vidor E. Poliovirus Vaccine–Inactivated. Plotkin's Vaccines. Elsevier; 2018. pp. 841-865.e10. [DOI: 10.1016/b978-0-323-35761-6.00047-x] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
33 Calvo Fernández E, Zhu LY. Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future. Br J Clin Pharmacol 2021;87:3408-24. [PMID: 33289156 DOI: 10.1111/bcp.14686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]